Sunshine Biopharma (NASDAQ:SBFMW – Get Free Report) is expected to be announcing its results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $10.00 million for the quarter.
Sunshine Biopharma Stock Performance
Shares of SBFMW stock opened at $0.16 on Tuesday. Sunshine Biopharma has a 12-month low of $0.11 and a 12-month high of $0.98. The firm’s 50 day moving average is $0.17 and its 200 day moving average is $0.19.
Sunshine Biopharma Company Profile
Sunshine Biopharma is a development-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics for oncology and antiviral applications. The company’s research activities encompass the design, synthesis and preclinical evaluation of compounds that inhibit key pathways involved in cell proliferation and viral replication.
Among its lead programs, Sunshine Biopharma is advancing Adva-27a, a topoisomerase II inhibitor licensed from the National Research Council of Canada, which is undergoing preclinical studies for potential use in breast and ovarian cancers.
Further Reading
- Five stocks we like better than Sunshine Biopharma
- Elon Musk already made me a “wealthy man”
- Elon’s Secret AI Partner?
- Silver $500? The “Deficit Math” says it’s possible.
- Unlocked: Elon Musk’s Next Big IPO
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
